AI-Driven Personalization Moves From Promise to Practice in Digital Health
Hims & Hers Health is leaning hard into AI, data infrastructure and personalization to deliver a next-generation care experience. Its proprietary stack pulls in electronic medical records, provider-built algorithms and real-time analytics to create individualized treatment paths. The result: adaptive recommendations, precise follow-ups and continuous tuning based on patient feedback and outcomes. The aim is simple - keep empathy at the center while improving efficiency and access.
Hims & Hers: Building an intelligent care engine
In 2025, the company appointed Mo Elshenawy as CTO to push deeper into automation and intelligent diagnostics. Under his leadership, tools are being built to connect diagnosis, treatment and delivery in one flow - consistent with CEO Andrew Dudum's vision of standardizing personalized, high-quality care at scale.
Hims & Hers also completed an $870 million convertible notes offering to fund data infrastructure and personalized treatment technologies. You can already see it in market: Hims' personalized oral testosterone program and Hers' menopause and perimenopause specialty use data-driven models to fit therapy to individual needs. Together, these moves point to a more precise, affordable and accessible consumer care model.
Doximity: Personalization inside clinical workflows
Doximity is expanding AI across its physician platform. AI Scribe accelerates documentation while adhering to HIPAA. The 2025 acquisition of Pathway brings one of the largest structured medical datasets into the mix, strengthening evidence-based answers.
Pathway's corpus flows into Doximity GPT for point-of-care support. Net effect: more accurate, context-aware assistance that reduces clicks and helps clinicians get to decisions faster.
Amwell: Data-driven hybrid care at scale
Amwell's Converge platform uses AI and analytics to personalize care, automate workflows and guide treatment decisions across major health systems and payers. In 2025, the company expanded automation and personalization features that support efficient hybrid models.
Its AI-enabled tools are also in use across the U.S. Military Health System, improving access, throughput and continuity for millions. For large, distributed populations, this kind of orchestration matters.
What this means for care teams
- Close the loop on care: automated follow-ups, symptom tracking and real-time adjustments based on outcomes.
- Reduce admin drag: AI scribing and workflow automation free up clinician time for higher-value work.
- Standardize quality: provider-built algorithms and large datasets reinforce consistent, evidence-based decisions.
- Scale hybrid care: seamless handoffs between virtual and in-person visits, medication delivery and ongoing monitoring.
- Governance first: set clear PHI policies, audit trails and model performance metrics to maintain safety and trust.
HIMS price performance, valuation and estimates
Year to date, HIMS shares are up 104.1%, versus 28.2% for the broader industry. The forward 12-month P/S sits at 4.1x, below the industry average of 5.9x but above the three-year median of 2.5x. It carries a Value Score of D.
The Zacks Consensus Estimate for 2025 EPS points to a 118.5% improvement over 2024. Hims & Hers currently holds a Zacks Rank #3 (Hold).
Signals to watch next
- Measured outcomes: time-to-therapy, adherence, PROs and readmissions tied to AI-guided pathways.
- Safety and bias: external validation of models, drift monitoring and clear escalation to clinicians.
- Interoperability: smooth integration with EHRs, pharmacies and logistics to close care gaps.
- Clinician adoption: time saved, note quality, and burnout trends with AI scribing and decision support.
- Payment models: payer coverage for AI-augmented services and hybrid care workflows.
If your team is building clinical AI fluency, explore curated programs by role at Complete AI Training. Small, focused upskilling goes a long way when workflows and outcomes are on the line.
Your membership also unlocks:
